Recombination interferons role

Lyseng-Williamson, K. and Plosker, G. 2002. Management of relapsing-remitting multiple sclerosis - defining the role of subcutaneous recombinant interferon-(3-la (Rebif). Disease Management and Health Outcomes 10(5), 307-325. 

In addition to the underlying disease, there are many potential susceptibility factors (499,519). There is as yet no definitive evidence that age, sex, dose, and duration of treatment play an important role in the development of thyroid disorders. However, patients with previous thyroid abnormalities are predisposed to develop more severe thyroid disease (SEDA-20, 328). The incidence of thyroid disease was not different between natural and recombinant interferon alfa. Although this should be taken into account, a previous familial or personal history of thyroid disease was generally not considered a major risk factor. Finally, only pre-treatment positivity or the development of thyroid antibodies during treatment seem to be strongly associated with the occurrence of thyroid dysfunction. 

Wadler S, Wiemik PH. Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma. Semin Oncol 1990 17(1 Suppl 1) 16-21. 

Steinbeck, M. J., Webb, D. S. A., Roth, J. A. (1989). Role for arachidonic acid metabolism and protein synthesis in recombinant bovine interferon- /induced activation of bovine neutrophils. J. Leuk. Biol. 46, 450-60. 

This section describes the role of interferons as cancer drug therapies, emphasizing key contributions of recombinant biotechnology that made these therapeutic advances a reality. Additionally, some of the mechanisms by which the IFNs elicit antiproliferative or antitumor effects wiU be explored. 

Arakawa T, Hsu YR, Parker CG, Lai PH. Role of polycationic C-terminal portion in the structure and activity of recombinant human interferon gamma. J Biol Chem 1986 261 8534-8539. 

---